{"entity":{"id":"nct05990127","kind":"trial","name":"A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 3 trial of cadonilimab, tislelizumab, carboplatin, pemetrexed and other drugs in lung cancer, run by Akeso, not yet recruiting.","summary":"A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT05990127 by Akeso, with a registry enrolment figure of 642 participants, started 2023-11-14 and due to reach its primary completion in 2025-08-05. Interventions recorded: AK104; Tislelizumab; carboplatin; Pemetrexed; Paclitaxel. Conditions listed: Locally Advanced or Metastatic NSCLC. Primary outcome: Overall Survival(OS); Progression-Free Survival(PFS) by investigator(INV). Lung eligibility wording from the registry: \"Histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC) that not amenable to complete surgical resection and not amenable to radical concurrent/sequential chemoradiation or metastatic (Stage IV) NSCLC (American Joint Committee on Cancer \\[AJCC\\] 8th edition)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05990127","url":"https://clinicaltrials.gov/study/NCT05990127"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["bispecific-antibody","checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["cadonilimab","tislelizumab","carboplatin","pemetrexed","paclitaxel"],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05990127","phase":"3","setting":"A Randomized, Double-blind, Phase III Trial to Compare the Efficacy and Safety of AK104 Combined With Chemotherapy to Tislelizumab Combined With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer (NSCLC)","sponsor":"Akeso","enrolled":642,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05990127/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"cadonilimab","kind":"drug","name":"Cadonilimab","route":"/drugs/cadonilimab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}